Robert Lorne Hopfner

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
San Francisco, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Gregory S. Moss, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Robert Lorne Hopfner

Form 4 holding Director, 10%+ Owner

Evommune, Inc.

Security class
Common Stock
Shares / value
1,632,441
Estimated value
$30,608,268
Report date
19 Dec 2025
Price
$18.75
Ownership
By Pivotal bioVenture Partners Fund I, L.P.
Form 4 holding Director, 10%+ Owner

Evommune, Inc.

Security class
Common Stock
Shares / value
1,441,032
Estimated value
$27,019,350
Report date
19 Dec 2025
Price
$18.75
Ownership
By NFLS Delta III Limited
Form 4 holding Director, 10%+ Owner

Evommune, Inc.

Security class
Common Stock
Shares / value
294,502
Estimated value
$5,521,912
Report date
19 Dec 2025
Price
$18.75
Ownership
By Pivotal bioVenture Partners Fund II, L.P.
Form 4 holding Director

Rallybio Corp

Security class
Option (Right to Buy)
Shares / value
28,500
Estimated value
$51,500
Report date
13 May 2025
Price
$0.7000
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Rallybio Corp

Security class
Option (Right to Buy)
Shares / value
16,500
Estimated value
$29,205
Report date
15 May 2024
Price
$1.77
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Vaxcyte, Inc.

Security class
Stock Option (right to buy)
Shares / value
15,000
Estimated value
Report date
02 Jun 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Evommune, Inc.

Security class
Series A Preferred Stock
Shares / value
0
Estimated value
Report date
07 Nov 2025
Price
Ownership
By NFLS Delta III Limited
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Evommune, Inc.

Security class
Series A Preferred Stock
Shares / value
0
Estimated value
Report date
07 Nov 2025
Price
Ownership
By Pivotal bioVenture Partners Fund I, L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Evommune, Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
07 Nov 2025
Price
Ownership
By NFLS Delta III Limited
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Evommune, Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
07 Nov 2025
Price
Ownership
By Pivotal bioVenture Partners Fund I, L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Evommune, Inc.

Security class
Series C Preferred Stock
Shares / value
0
Estimated value
Report date
07 Nov 2025
Price
Ownership
By NFLS Delta III Limited
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Evommune, Inc.

Security class
Series C Preferred Stock
Shares / value
0
Estimated value
Report date
07 Nov 2025
Price
Ownership
By Pivotal bioVenture Partners Fund II, L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Evommune, Inc.

Security class
Series C Preferred Stock
Shares / value
0
Estimated value
Report date
07 Nov 2025
Price
Ownership
By Pivotal bioVenture Partners Fund I, L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Evommune, Inc.

Security class
Series Seed Preferred Stock
Shares / value
0
Estimated value
Report date
07 Nov 2025
Price
Ownership
By NFLS Delta III Limited
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Evommune, Inc.

Security class
Series Seed Preferred Stock
Shares / value
0
Estimated value
Report date
07 Nov 2025
Price
Ownership
By Pivotal bioVenture Partners Fund I, L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Evommune, Inc.

Security class
Series Seed Preferred Stock
Shares / value
0
Estimated value
Report date
07 Nov 2025
Price
Ownership
By Trust
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Robert Lorne Hopfner

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .